Dendritic cell fusion vaccines for cancer immunotherapy.

@article{Rosenblatt2005DendriticCF,
  title={Dendritic cell fusion vaccines for cancer immunotherapy.},
  author={Jacalyn Rosenblatt and Donald Kufe and David Avigan},
  journal={Expert opinion on biological therapy},
  year={2005},
  volume={5 5},
  pages={
          703-15
        }
}
The use of tumour vaccines is being explored as a means of generating effective antitumour immune responses in patients with cancer. Dendritic cells (DCs) are the most potent antigen-presenting cells that are essential for initiating primary immune responses. As such, DCs are being studied as a platform for the design of cancer vaccines. DCs loaded with tumour antigens or whole tumour cell derivatives stimulate tumour-specific immunity. A promising vaccine strategy involves the fusion of DCs… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 16 CITATIONS

Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell/AML vaccine.

Myrna R. Nahas, Dina Stroopinsky, +18 authors David Avigan
  • British journal of haematology
  • 2019
VIEW 1 EXCERPT
CITES BACKGROUND

Microfluidic chip for rapid electrofusion of homogeneous and heterogeneous cells

  • 2015 Transducers - 2015 18th International Conference on Solid-State Sensors, Actuators and Microsystems (TRANSDUCERS)
  • 2015
VIEW 1 EXCERPT
CITES BACKGROUND